IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win(R) Immunotherapy in Non-small Cell Lung Cancer

COPENHAGEN, Denmark, May 15, 2019 -- (Healthcare Sales & Marketing Network) -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the i... Biopharmaceuticals, Oncology IO Biotech, NSCLC, Immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news